His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the PI of the PROTECT study, investigating cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma. He recently completed the PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. He is intimately involved in the latest treatment trials for cardiac amyloidosis. He recently moved to Washington University in St. Louis to enhance and expand the Cardio-Oncology Center of Excellence. Dr. Lenihan is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.